Hims & Hers Health, a telehealth company, saw its shares fall 9% in extended trading after reporting second-quarter results that missed Wall Street’s expectations for revenue. The company reported revenue of $544.8 million, up 73% from the same period last year, but below the expected $552 million.
Hims & Hers’ adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) came in at $82 million, above StreetAccount’s estimate of $73 million. The company reported an earnings per share of 17 cents, which was slightly higher than the expected 15 cents.
The stock drop comes as the company faces controversy over its sale of compounded GLP-1s, cheaper, unapproved versions of diabetes and weight loss medications. Despite ongoing supply issues being resolved by the US FDA in February, some telehealth companies continue to offer these medications.
Hims & Hers will host a quarterly call with investors on Monday at 5 p.m. ET to discuss its results. The company’s shares have tumbled over 30% since June after a failed collaboration with Novo Nordisk.
Source: https://www.cnbc.com/2025/08/04/hims-hers-hims-q2-earnings-2025.html